Business ❯ Pharmaceuticals

Acquisitions

Sanofi Mergers and Acquisitions Drug Development Novartis Biotechnology Merck Corporate Strategy Market Trends AbbVie Novo Nordisk Bristol Myers Squibb Market Strategy Pfizer Rare Diseases BioNTech Merck & Co. Biotech Companies Vertex Pharmaceuticals Cancer Treatment Cancer Treatments Market Valuation Genetics Eli Lilly Genetic Testing Obesity Treatments Biopharmaceuticals Ophthalmology Biontech Data Privacy Merck Group Market Dynamics Biopharma JB Chemicals Private Equity Biopharmaceutical Companies Psychedelic Treatments Clinical Development Biopharma Industry Weight Loss Drugs Partnerships Biogen Obesity Drugs Organon & Co Merus Strategic Partnerships Zydus Lifesciences Regulatory Approval Intellectual Property Company History Competition Vaccine Development Vaccine Industry Corporate Finance Market Competition COVID-19 Impact Mergers Biotech Icosavax Acquisition Icosavax AstraZeneca PLC First Wave BioPharma Inc Clinical Trials Genmab AstraZeneca

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

The $14-per-share agreement brings Lilly a clinical portfolio targeting chronic inflammation, with closing targeted in the first half of 2026.

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Novartis to Buy Avidity Biosciences for $12 Billion, Adding Muscle-Targeted RNA Drugs

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs

Biogen to Buy Alcyone for $85 Million, Gaining Rights to ThecaFlex DRx

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion